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Olfactory cleft inflammation present in seasonal allergic rhinitis & intranasal steroids
Anita Sivam

PURPOSE: Allergic rhinitis (AR) is commonly associated with olfactory loss, although the mechanism
is not well studied. This study was designed to determine the effect of mometasone furoate (MF) on olfactory loss in seasonal AR (SAR) and to study its effect on inflammation in the olfactory region.
METHODS: We performed a randomized, double-blind, placebo-controlled, parallel clinical trial in 17
patients with SAR who had symptoms of impaired olfaction (Table 1). Subjects received MF or placebo
for 2 weeks during their allergy season. Before and after treatment, we measured nasal peak inspiratory
flow (NPIF), chemosensory quality of life, and objective olfactory function (the University of Pennsylvania Smell Identification Test) (Figure 1). Additionally, nasal cytology samples were obtained from
each visit, and a unilateral endoscopic biopsy specimen of the olfactory epithelium was obtained at the
end of the study and scored for inflammation.
RESULTS: Treatment with MF was associated with improved nasal symptoms (p < 0.015) (Figure 2a),
NPIF (p < 0.04) (Figure 2b), reduced nasal inflammation (p < 0.05) (Figure 2c), and chemosensoryspecific quality of life (p < 0.03) (Figure 3). Histological analysis of the olfactory region reveals fewer
eosinophils in the MF group when compared with placebo (p < 0.012). We found no improvement in
objective olfactory function (p > 0.05).
CONCLUSION: The use of MF in SAR is associated with reduced eosinophilic inflammation in the
olfactory region and improved symptoms of AR. The presence of eosinophils in the olfactory area in
SAR may indicate a direct, deleterious effect of inflammation on olfactory epithelium in this disease. In
this study, we show that inflammation in SAR can affect the olfactory cleft, implicating a direct role for
allergic inflammation in smell loss. Treatment with intranasal steroids is associated with decreased
inflammation in the olfactory region in humans.
Table 1. Characteristics of the Study Population.
Mometasone Furoate
(n=8)

Demographics

Placebo

40 (24-49)

(n=9)
38 (23-52)

P=0.752

Male n/%

2 (25)

5 (56)

P=0.201

Ragweed n/%

5 (63)

6 (66)

Grass n/%

3 (37)

3 (33)

Chemosensory QOL (mean±SEM)

24.3 ± 0.808

28.7 ± 1.92

P=0.078

UPSIT Raw Score (median, range)

32 (27-37)

31 (17-37)

P=0.459

NPIF (median, range)

103 (90-147)

118 (67-191)

P=0.224

TNSS (median, range)

16.5 (13-26)

12 (6-26)

P=0.440

Eosinophils (median, range)

1.55 (0.5-4)

0.5 (0-1.5)

P=0.028

Age (mean, range), y
Allergen Sensitivity

Baseline Values

103
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Figure 1. Study Design. Both treatments were daily nasal sprays given in the morning. NPIF indicates
nasal peak inspiratory flow, QOL, quality of life, UPSIT, University of Pennsylvania Smell Identification Test.
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Figure 2a. Change in total nasal symptom
score from initial visit to two-week treatment
with mometasone or placebo. Individual data
points are depicted with the horizontal bars
representing medians. Mometasone led to greatreduction of symptoms than placebo.

Anita Sivam: Olfactory Cleft Inflammation & Intranasal Steroids

Change in NPIF
60

P<0.0

40

Figure 2b. Nasal peak inspiratory flow (NPIF).
Regarding changes from initial visit for all measurements of NPIF, a negative number represents worsening, and a positive number represents improvement.
Horizontal bars depict medians.
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Figure 2c. Biopsy specimens were scored for inflammation by counting the number of eosinophils
in three high power fields, with the average reported. Subjects receiving MF showed significantly
reduced numbers of eosinophils in the olfactory region compared to placebo.
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Quality of Life Score

35
33
31

*

29
27
Placebo

25

Mometasone

23

V1

V2

Figure 3. Change in chemosensory quality of life (QOL). The overall quality-of-life score calculated
from the Coping Style Questionnaire (CSQ) is shown. Mean ± SEM for the 2 groups at enrollment (V1)
and after 2 weeks of treatment (V2). Increases on the y-axis indicate better quality of life.
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